Comparative Pharmacology
Head-to-head clinical analysis: INDOCIN versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOCIN versus LODINE.
INDOCIN vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. It also decreases renal blood flow and may cause ductus arteriosus closure.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
25 mg orally 2-3 times daily; maximum 200 mg/day. Intravenous: 0.5-1 mg/kg as single dose for ductus arteriosus closure.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life approximately 4.5 hours (range 2.6–11.2 hours); prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Renal (60% as unchanged drug and glucuronide conjugates), biliary/fecal (33% via enterohepatic circulation).
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category C
Category C
NSAID
NSAID